Clinical Outcomes of Adjuvant Chemotherapy in Elderly Patients with Resected Stage II and III Colon Cancer: A Real Life Data

Authors : Mehmet Zahid Koçak, Murat Araz, Mustafa Karaağaç, Mustafa Korkmaz, Aykut Demirkıran, Engin Hendem, Melek Karakurt Eryılmaz, Mehmet Artaç

Pages : 623-629

Doi:10.20515/otd.1657501

View : 25 | Download : 15

Publication Date : 2025-06-18

Article Type : Research Paper

Abstract :This study aimed to evaluate the efficacy and tolerability of adjuvant chemotherapy in clinical practice in the elderly patients with resected stage II and III colon cancer. Fifty-three resected stage II and III colon cancer patients respectively evaluated between August 2010 and September 2019 were included. The study population was divided into two group as received adjuvant chemotherapy and non-received group. Clinical features, overall survival (OS) and disease-free survival (DFS) were compared between groups. Cox regression analysis was used to determine independent risk factors for OS. The hazard ratio (HR) for OS in the group given adjuvant chemotherapy, as compared with non-received group, was 0.80 (95% Confidence interval [CI]: 0.66-0.90) (p=0.0025), corresponding to a 20 percent reduction in the risk of mortality. There was no statistically significant difference between the DFS of these groups (HR:1.02, 95% CI: 0.75-1,35) (p=0.96). In multivariate (age, perforation, obstruction, disease stage, adequate lymph node, tumor side) and univariate analysis, age was not an independent predictive marker for OS. Adjuvant chemotherapy was effective and its toxicity manageable for elderly patients both stage II and stage III colon cancer. Adjuvant chemotherapy decisions should be based on a biological age and functional assessment of the patient than chronological age.
Keywords : kolon kanseri, adjuvan kemoterapi, toksisite, yaşlı hasta

ORIGINAL ARTICLE URL